Roche gets FDA nod for Lunsumio, offering convenient option to gene therapies in follicular lymphoma

Upon the FDA approval for its bispecific antibody Lunsumio (mosunetuzumab) as a third-line therapy for follicular lymphoma, Roche was quick to point out that its treatment was an “off-the-shelf, accessible” option.